Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.56 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8465670 | 0.93 | LMNA (0.64) | LMNASMN1; SMN2NPC1RECQLRAB9A | |
| SCHEMBL7629438 | 0.90 | LMNA (0.60) | LMNASMN1; SMN2NPC1RECQLRAB9A | |
| SCHEMBL7319637 | 0.89 | TDP1 (0.75) | LMNASMN1; SMN2NPC1RECQLRAB9A | |
| SCHEMBL451184 | 0.88 | TDP1 (0.68) | LMNASMN1; SMN2NPC1RECQLRAB9A | |
| SCHEMBL27852689 | 0.87 | TDP1 (0.68) | LMNASMN1; SMN2NPC1RECQLRAB9A | |
| SCHEMBL2540241 | 0.87 | TDP1 (0.85) | LMNASMN1; SMN2NPC1RECQLRAB9A | |
| SCHEMBL27360871 | 0.87 | LMNA (0.66) | LMNASMN1; SMN2NPC1RECQLRAB9A | |
| SCHEMBL13997917 | 0.87 | TDP1 (0.72) | LMNASMN1; SMN2NPC1RECQLRAB9A | |
| SCHEMBL3396096 | 0.87 | LMNA (0.66) | LMNASMN1; SMN2NPC1RECQLRAB9A | |
| SCHEMBL7367695 | 0.87 | LMNA (0.57) | LMNASMN1; SMN2NPC1RECQLRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105980345-B | Method for continuously producing ketomalonic acid compound using flow reactor | 组合化学工业株式会社 | 2019-12-20 | — | — | CN | disclosed |
| EP-2476682-B1 | 8-OXODIHYDROPURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-04-26 | — | — | EP | disclosed |
| US-8735406-B2 | 8-oxodihydropurine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2476682-A1 | 8-OXODIHYDROPURINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| CN-101115731-A | Oxadiazole derivatives as DGAT inhibitors | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | CN | disclosed |
| US-5886024-A | ENZYME INHIBITOR FOR TREATING ARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, DYSTROPHOBIC EPIDERMOLYSIS BULLOSA | BAYER CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| US-5886022-A | TREATMENT OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, DYSTROPHOBIC EPIDERMOLYSIS BULLOSA | BAYER CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| US-5886043-A | ANTIARTHRITIC AGENTS, ANTITUMOR AGENTS, ANTIINFLAMMATORY AGENTS | BAYER CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| US-5874473-A | OSTEOPOROSIS; ANTIARTHRITIC AGENTS | BAYER CORPORATION (US) | 1999-02-23 | — | — | US | disclosed |
| US-5861428-A | ALLEVIATION OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, DYSTROPHOBIC EPIDERMOLYSIS BULLOSA, INFLAMMATION, OSTEOPENIAS, TEMPERO | BAYER CORPORATION (US) | 1999-01-19 | — | — | US | disclosed |
| US-5861427-A | ALLEVIATION OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, DYSTROPHOBIC EPIDERMOLYSIS BULLOSA, CONDITIONS LEADING TO INFLAMMATORY | BAYER HEALTHCARE LLC | 1999-01-19 | — | — | US | disclosed |
| US-5859047-A | ANTIARTHRITIC AGENTS, NERVOUS SYSTEM DISORDERS | BAYER CORPORATION (US) | 1999-01-12 | — | — | US | disclosed |
| US-5854277-A | Thiophenebutanoic acid derivatives as matrix metalloprotease inhibitors | BAYER CORPORATION (US) | 1998-12-29 | — | — | US | disclosed |
| EP-0489933-A1 | BILE ALCOHOL AND DRUG CONTAINING THE SAME AS ACTIVE INGREDIENT | TSUMURA CO., LTD. (JP) | 1992-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | FAAH, FAAH2, TPMT | LMNA 3252/4885SMN1; SMN2 2425/4885NPC1 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.